Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.

Authors

Patrick S Sullivan
Robertino Mera Giler
Farah Mouhanna, George Washington University
Elizabeth S Pembleton
Jodie L Guest
Jeb Jones
Amanda D Castel, George Washington University
Howa Yeung
Michael Kramer
Scott McCallister
Aaron J Siegler

Document Type

Journal Article

Publication Date

12-1-2018

Journal

Annals of epidemiology

Volume

28

Issue

12

Inclusive Pages

833-840

DOI

10.1016/j.annepidem.2018.06.009

Keywords

Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; United States

Comments

Epub 2018 Jun 22

APA Citation

Sullivan, P., Giler, R., Mouhanna, F., Pembleton, E., Guest, J., Jones, J., Castel, A., Yeung, H., Kramer, M., McCallister, S., & Siegler, A. (2018). Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.. Annals of epidemiology, 28 (12). http://dx.doi.org/10.1016/j.annepidem.2018.06.009

Peer Reviewed

1